title: Breast Molecular Profiling and Radiotherapy Considerations.
abstract: The last decade has seen major changes in the management of breast cancer. Heterogeneity regarding histology, therapeutic response, dissemination patterns, and patient outcome is evident. Molecular profiling provides an accurate tool to predict treatment outcome compared with classical clinicopathologic features. The genomic profiling unveiled the heterogeneity of breast cancer and identified distinct biologic subtypes. These advanced techniques were integrated into the clinical management; predicting systemic therapy benefit and overall survival. Utilizing genotyping to guide locoregional management decisions needs further characterization. In this chapter we will review available data on molecular classification of breast cancer, their association with locoregional outcome, their radiobiological properties and radiotherapy considerations.
authors.affiliation: Department of Radiation Oncology, Robert Wood Johnson Medical School, New Jersey Medical School and Rutgers Cancer Institute of New Jersey, NJ, New Brunswick, USA.
authors.forename: Omar
authors.initials: O
authors.lastname: Mahmoud
authors.affiliation: Department of Radiation Oncology, Robert Wood Johnson Medical School, New Jersey Medical School and Rutgers Cancer Institute of New Jersey, NJ, New Brunswick, USA. hafftybg@cinj.rutgers.edu.
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Haffty
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D020022:Genetic Predisposition to Disease; D006801:Humans; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D010641:Phenotype; D011237:Predictive Value of Tests; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor
keywords: Breast cancer; Molecular signature; Radiotherapy; Subtyping